David
Co-Founder
The article, "Optimizing Azathioprine Therapy in IBD Patients" by Carmen Cuffari is found on pages 661-665 of the book, "Advanced Therapy in Inflammatory Bowel Disease" and is supported by 29 references. For any of you interested in the deeper medical side of Crohn's Disease, this book is fantastic. This thread will contain information I feel is useful in the article and I also open it up for discussion.
- "Critical-dose drugs" are medications that are metabolized differently by a different patients. 6-MP and Azathioprine are critical-dose drugs.
- [wiki]6-TGTP[/wiki] (read that link if you want your brain to explode) is a metabolite of 6-TGN that they think may be what makes 6-MP and Azathioprine work. They feel that some people have different levels of enzyme production associated with it which may be why some people have therapeutic levels of 6-TGN in their system but 6-MP/Azathioprine still don't work well.
- The primary reasons to optimize AZA and 6-MP dosage is to improve response, shorten the response time, and minimize the chance of side effects.
- 40-70% of Crohn's Disease and Ulcerative Colitis patients have therapeutic responses to AZA or 6-MP.
- 6-TGN levels of greater than 250 pmol/8 x 10^8 RBCs in patients correlated with a lack of symptoms. Patients with low levels don't do well. One patient with low levels was suspected not to be taking their meds which they later admitted to. Hahah! 6-TGN monitoring plain makes sense.
- 11% of patients are heterozygous carriers of the TPMT deficient allele and at increased risk of [wiki]leukopenia[/wiki] -- a lower dose of 1 mg/kg/day has been shown to achieve a favorable clinical response in these patients.
- Homozygous recessive patients are at great risk of irreversible bone marrow myelosuppression.
- 50% of the population metabolize AZA and 6-MP normally.
- TPMT testing has been shown to predict leukopenia in up to 20% of patients.
- Patients with no TPMT activity should not be given AZA. Those with levels less than 5 should get 1 mg/kg/day. Those with levels between 5 and 12 can get 1.5 mg/kg/day. Those with levels between 12 and 16 can get 2.0 mg/kg/day. Those with greater than 16 can get 2.5 mg/kg/day
- Metabolite monitoring of 6-TGN and 6-MMP can explain poor response to AZA and 6-MP.
- In a study of 25 patients who weren't responding to AZA but had low levels of 6-TGN, when their dose was increased by 25mg/day 18 reached remission.
- Editors note says that he monitors the WBC and if it is 7000 in a non responsive patient then he increases AZA by 25mg/day until the WBC is 6000 or less then he monitors 6-TGN. I assume this is because 6-TGN testing is expensive.
- "Critical-dose drugs" are medications that are metabolized differently by a different patients. 6-MP and Azathioprine are critical-dose drugs.
- [wiki]6-TGTP[/wiki] (read that link if you want your brain to explode) is a metabolite of 6-TGN that they think may be what makes 6-MP and Azathioprine work. They feel that some people have different levels of enzyme production associated with it which may be why some people have therapeutic levels of 6-TGN in their system but 6-MP/Azathioprine still don't work well.
- The primary reasons to optimize AZA and 6-MP dosage is to improve response, shorten the response time, and minimize the chance of side effects.
- 40-70% of Crohn's Disease and Ulcerative Colitis patients have therapeutic responses to AZA or 6-MP.
- 6-TGN levels of greater than 250 pmol/8 x 10^8 RBCs in patients correlated with a lack of symptoms. Patients with low levels don't do well. One patient with low levels was suspected not to be taking their meds which they later admitted to. Hahah! 6-TGN monitoring plain makes sense.
- 11% of patients are heterozygous carriers of the TPMT deficient allele and at increased risk of [wiki]leukopenia[/wiki] -- a lower dose of 1 mg/kg/day has been shown to achieve a favorable clinical response in these patients.
- Homozygous recessive patients are at great risk of irreversible bone marrow myelosuppression.
- 50% of the population metabolize AZA and 6-MP normally.
- TPMT testing has been shown to predict leukopenia in up to 20% of patients.
- Patients with no TPMT activity should not be given AZA. Those with levels less than 5 should get 1 mg/kg/day. Those with levels between 5 and 12 can get 1.5 mg/kg/day. Those with levels between 12 and 16 can get 2.0 mg/kg/day. Those with greater than 16 can get 2.5 mg/kg/day
- Metabolite monitoring of 6-TGN and 6-MMP can explain poor response to AZA and 6-MP.
- In a study of 25 patients who weren't responding to AZA but had low levels of 6-TGN, when their dose was increased by 25mg/day 18 reached remission.
- Editors note says that he monitors the WBC and if it is 7000 in a non responsive patient then he increases AZA by 25mg/day until the WBC is 6000 or less then he monitors 6-TGN. I assume this is because 6-TGN testing is expensive.